Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Hollow Microstructured Transdermal System Delivers Biopharmaceuticals

By Drug Discovery Trends Editor | December 7, 2009

hiw-1.jpg

click to enlarge

Figure 1: Hollow microstructured transdermal system attached to user. (Source: 3M Drug Delivery Systems) 

In recent years, many therapeutic peptides and proteins have come to market. While they are highly effective, these drugs must often be administered by IV or syringe injection. This complicates the administration process and can potentially affect patient compliance. At the same time, traditional transdermal patch technologies are only capable of delivering smaller, lipophilic molecules that diffuse through the stratum corneum and pass into systemic circulation. Few active pharmaceutical ingredients (APIs) are compatible with this method of delivery, particularly biopharmaceuticals. However, a new transdermal delivery system is showing promise for the administration of these drugs.

A hollow microstructured transdermal system (hMTS) uses hollow microstructures to penetrate the stratum corneum and provide fast, high-volume intradermal delivery of molecules traditionally restricted to syringe injection. The hMTS provides a comfortable and repeatable means of administering intradermal delivery of small-molecule salts, peptides, proteins (including antibodies), and molecules not readily compatible with oral, pulmonary, or traditional transdermal delivery technologies.

hiw-2.jpg

click to enlarge

Figure 2: Comparison of different infusion methods charted against time. (Source: 3M Drug Delivery Systems) 

The device is designed for self-administration and integrates application of the small polymeric microstructures with a traditional glass API reservoir, along with a means of powering the intradermal delivery via a spring incorporated into the device. The disposable device is designed for home-based self administration to the upper arm or upper thigh (Figure 1).

The hMTS accesses the intradermal space, providing fast and efficient delivery into the systemic circulation. To overcome the barrier properties of the stratum corneum, the device utilizes biocompatible, medical-grade, polymeric microstructures.

These microstructures are modeled as mini hypodermic needles, 500 to 900 µm tall. Eighteen structures are configured across a 1 cm2 array, providing a diffuse area for intradermal infusion. Upon application, these structures penetrate the stratum corneum and pass through the epidermis into the dermis, well above the nerve endings that could cause discomfort.  Following application, a relatively high volume of liquid formulation (0.5 to 1 mL) is delivered into the dermis, after which the device is removed. The device accommodates a traditional 1-mL glass cartridge as a reservoir for the formulation and is intended to be worn throughout the delivery period, which can range from 5 to 40 minutes depending on the formulation. An adhesive on the device enables it to stick to the skin during the required wear period. The depth of penetration associated with the hMTS integrated device ranges from 275 to 650 micrometers, depending on the length of the structures. Channels in each structure allow for fluid communication between the top and bottom of the array, offering a means for effectively and painlessly delivering liquid formulations into the skin.

Research shows the hMTS array has sufficient strength to penetrate the stratum corneum and sufficient flexibility to prevent fracture of the microstructures. The microstructures maintain integrity during insertion studies conducted in swine, hairless guinea pigs, and humans. Under extreme force, the microstructures will bend rather than fracture or break off, as might be expected from microstructures made of glass or metal. 

The hMTS device has been used to provide efficient and fast in-vivo delivery of small-molecule salts and proteins, including high-molecular weight antibodies. hMTS delivery allows administration to be accomplished with the efficiency of a syringe, along with the patient-friendly characteristics of a transdermal patch (Figure 2). The system, which is not yet commercially available, has the potential to offer patients a means for simple, home-based self administration.

References
1. Prausnitz MR. Microneedles for transdermal delivery. Advanced Drug Delivery Reviews. 2004; 56:581-587.
2. David SP, Landis BJ, Adams ZH, Allen MG, Prausnitz MR. Insertion of microneedles into skin: measurement and prediction of insertion force and needle fracture force. J Biomech. 2004; 37:115-1163.

This article was published in Drug Discovery & Development magazine: Vol. 12, No. 10, November/December 2009, p. 34.

 


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE